PPARgamma and the thiazolidinediones: molecular basis for a treatment of 'Syndrome X'?
Sewter
C
C
University of Cambridge, Departments of Clinical Biochemistry and Medicine, Addenbrooke's Hospital, Cambridge, UK.
Vidal-Puig
A
A
D000818:Animals; D006801:Humans; D007333:Insulin Resistance / Q000502:physiology*; D024821:Metabolic Syndrome / Q000188:drug therapy*; D008830:Microbodies / Q000502:physiology; D018160:Receptors, Cytoplasmic and Nuclear / Q000502:physiology*; D013844:Thiazoles / Q000627:therapeutic use*; D014157:Transcription Factors / Q000502:physiology*
D018160:Receptors, Cytoplasmic and Nuclear; D013844:Thiazoles; D014157:Transcription Factors